Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) Director Ping Ji sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total transaction of $159,900.00. Following the completion of the sale, the director owned 121,453 shares in the company, valued at $1,942,033.47. This represents a 7.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Ping Ji also recently made the following trade(s):
- On Tuesday, September 29th, Ping Ji sold 214 shares of Adlai Nortye stock. The shares were sold at an average price of $15.77, for a total value of $3,374.78.
- On Tuesday, September 22nd, Ping Ji sold 5,000 shares of Adlai Nortye stock. The shares were sold at an average price of $16.63, for a total transaction of $83,150.00.
Adlai Nortye Stock Down 1.5%
Shares of NASDAQ ANL traded down $0.23 during mid-day trading on Thursday, reaching $15.77. 9,308 shares of the company were exchanged, compared to its average volume of 364,887. The company’s 50 day moving average price is $14.23 and its 200 day moving average price is $12.20. Adlai Nortye Ltd. Sponsored ADR has a 52 week low of $0.88 and a 52 week high of $17.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55.
Hedge Funds Weigh In On Adlai Nortye
Analyst Ratings Changes
Several analysts recently issued reports on the company. Wall Street Zen downgraded Adlai Nortye from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Jefferies Financial Group began coverage on shares of Adlai Nortye in a research note on Thursday, September 10th. They issued a “buy” rating and a $31.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a research report on Tuesday, September 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Finally, Loop Capital set a $49.00 price objective on shares of Adlai Nortye in a report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.50.
View Our Latest Stock Analysis on Adlai Nortye
Adlai Nortye Company Profile
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.
Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.
Read More
- Five stocks we like better than Adlai Nortye
- Micron’s Earnings Reveal Why the AI Memory Boom May Last Longer
- Hobby Boom or Travel Bust? Here Are 3 Stocks to Ride the Trend
- Jabil’s Double-Beat and Raise Is a Signal That This Rally Will Continue
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
